WO2018059214A1 - 影响saicar合成的化合物及应用 - Google Patents

影响saicar合成的化合物及应用 Download PDF

Info

Publication number
WO2018059214A1
WO2018059214A1 PCT/CN2017/101062 CN2017101062W WO2018059214A1 WO 2018059214 A1 WO2018059214 A1 WO 2018059214A1 CN 2017101062 W CN2017101062 W CN 2017101062W WO 2018059214 A1 WO2018059214 A1 WO 2018059214A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceutically acceptable
compound
derivative
saicar
Prior art date
Application number
PCT/CN2017/101062
Other languages
English (en)
French (fr)
Inventor
潘武广
朱威
Original Assignee
广州君赫生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州君赫生物科技有限公司 filed Critical 广州君赫生物科技有限公司
Publication of WO2018059214A1 publication Critical patent/WO2018059214A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Definitions

  • This invention relates to compounds and applications that affect SAICAR synthesis.
  • Anthraquinone anabolism is a ubiquitous and important biological metabolism in organisms. Its products AMP and GMP not only provide raw materials for the biosynthesis of DNA and RNA in vivo, but also many key coenzymes in the body (NAD, NADP, FAD and CoA). ), signaling molecules (such as cAMP) and the important energy molecule ATP provide the purine bases necessary for its synthesis. It can be seen that hydrazine anabolism is at the core of the entire metabolic network. Indole synthesis includes two synthetic pathways, de novo purine synthesis and salvage pathway.
  • Adenyl succinate lyase deficiency is a metabolic disease that causes deletion and confusion in de novo synthesis of adenine and purine nucleotide metabolism.
  • the cause of the disease is mainly due to mutation or deletion of adenyl succinate lyase in the patient, resulting in excessive accumulation of the enzyme substrate SAICAR in the cell without timely clearance [Jaeken J, Van den Berghe G. (1984).
  • An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids. Lancet 8411: 1058-1061.].
  • ADSL deficiency has three consecutive major phenotypes: neonatal lethal, severe (type I) and mild to moderate (type II). It has been clinically found that even patients from the same family have different phenotypes. The onset is generally seen in the period from birth to infancy. The reported cases have fatal neonatal brain lesions (representing hypokinesia, refractory epilepsy, respiratory disorders), moderate intelligence Force defect. All patients have mental retardation, most of them have different types of epilepsy, and about one-third of them have autistic features (no eye contact, sensitivity to sound and light, repetitive behavior, agitation, temper tantrum, self-injury and Self-mutilation).
  • Clinical manifestations include delayed mental activity, hyperactivity, speech disorders, muscle tone loss, muscle atrophy, and paralysis. Severe patients usually have microcephaly. Prenatal clinical manifestations include: intrauterine growth impaired, microcephaly, fetal motor dysfunction, and fetal heart rate loss.
  • ADSL enzyme adenyl succinate lyase
  • SAICAr is the product of SAICAR dephosphorylation
  • S-Ado is the product of S-AMP dephosphorylation
  • PAICS phosphoribosylaminoimidazole succinocarboxamidesynthetase/phosphoribosylaminoimidazolecarboxylase
  • SAICAR synthetase The function of 4-(N-succinylcarboxamide)-5-aminoimidazole ribonucleotidesynthetase, SAICARs
  • AIRc AIR carboxylase
  • the inventors found that the DrugBank IDs were DB01661, DB01868, DB02578, DB02696, and DB02716 based on the existing protein structure data, which can effectively interfere with the activity of PAICS, thereby reducing the synthesis of SAICAR. Reduce the accumulation of SAICAr to achieve the purpose of treating or improving ADSL deficiency.
  • the pharmaceutically acceptable derivative of the above compound has the same core structure as the compound itself, and undergoes hydrolysis or the like in the body to form a molecule having the same or similar activity as the original compound, achieving the same or similar therapeutic effects.
  • a pharmaceutically acceptable derivative of a compound especially a simple derivative thereof, particularly one of a lower ester, a lower ether, a lower alkyl substituent, a pharmaceutically acceptable salt, or a lower amide, that is, having 1 to 6 carbon atoms. It is preferably a derivative obtained by condensing a carboxylic acid, an alcohol or an amine of 2 to 6, 2 to 4 with a parent compound.
  • compositions of the compounds can be synthesized from the parent compound by conventional chemical methods, such as in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: The method described in 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • these salts can be prepared by reacting the free base of the compound with an acid in water or an organic solvent or a mixture of the two; usually, A non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is used.
  • Acid addition salts can be prepared by various acids (mineral acids and organic acids).
  • the acid addition salt include a salt made of an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), and L-aspartate.
  • benzenesulfonic acid benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, citric acid, hexanoic acid, Octanoic acid, cinnamic acid, citric acid, cyclaic acid, lauryl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactose Acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (such as D-glucuronic acid), glutamic acid (such as L-glutamic acid), ⁇ -ketoglutaric acid, glycolic acid, Hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionate
  • Figure 1 is a three-dimensional solid ribbon structure diagram of PAICS
  • FIG. 2 is a diagram showing the interaction of CAIR and SAICAR synthetase in crystal structure, in which A: PDB access ID 2GQS; B: PDB access ID 2CNQ; C: PDB access ID 4FE2;
  • Figure 3 is a result of alignment of different SAICAR synthase protein sequences.
  • the human PAICS protein sequence has a total length of 425 amino acid residues, of which 2 to 260AA is the SAICAR synthetase domain, 267-425 is the AIR carboxylase domain, and the two domains are linked by the 6-peptide (KSESQC).
  • KSESQC 6-peptide 6-peptide
  • the GLN159-GLN183 ⁇ helix of the SAICAR Synthetase domain interacts with the ASN395-ASN424 ⁇ helix of the AIR carboxylase domain, as shown in Figure 1.
  • the pharmaceutically acceptable derivative of the above compound has the same core structure as the compound itself, and undergoes hydrolysis or the like in the body to form a molecule having the same or similar activity as the original compound, achieving the same or similar therapeutic effects.
  • a pharmaceutically acceptable derivative of a compound especially a simple derivative thereof, particularly one of a lower ester, a lower ether, a lower alkyl substituent, a pharmaceutically acceptable salt, or a lower amide, that is, having 1 to 6 carbon atoms. It is preferably a derivative obtained by condensing a carboxylic acid, an alcohol or an amine of 2 to 6, 2 to 4 with a parent compound.
  • compositions of the compounds can be synthesized from the parent compound by conventional chemical methods, such as in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: The method described in 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • these salts can be prepared by reacting the free base of the compound with an acid in water or an organic solvent or a mixture of the two; usually, a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is used. .
  • Acid addition salts can be prepared by various acids (mineral acids and organic acids).
  • the acid addition salt include a salt made of an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), and L-aspartate.
  • benzenesulfonic acid benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, citric acid, hexanoic acid, Octanoic acid, cinnamic acid, citric acid, cyclaic acid, lauryl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactose Acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (such as D-glucuronic acid), glutamic acid (such as L-glutamic acid), ⁇ -ketoglutaric acid, glycolic acid, Hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionate
  • Combination therapy can improve the efficacy and reduce side effects.
  • two, three, four, five or more compounds or derivatives thereof can be used simultaneously as an active ingredient for treating ADSL deficiency.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

提供了影响SAICAR合成的化合物及应用。基于现有的蛋白结构数据、小分子结构数据，使用软件计算分析，筛选得到可以有效干扰PAICS活性的化合物，使用后可以减少SAICAR的合成，最终减少SAICAR的积累，达到治疗或改善ADSL缺陷症的目的。通过联合使用上述化合物中的至少两种，有望获得更佳的治疗或改善ADSL缺陷症的效果。

Description

影响SAICAR合成的化合物及应用 技术领域
本发明涉及影响SAICAR合成的化合物及应用。
背景技术
嘌呤合成代谢是生物体普遍存在而又十分重要的生物代谢，其产物AMP和GMP不仅为生物体内DNA和RNA的生物合成提供原料，而且也为体内许多关键的辅酶(NAD、NADP、FAD和CoA)、信号分子(如cAMP)和重要的能量分子ATP提供其合成所必需的嘌呤碱基。可见，嘌呤合成代谢在整个代谢网络中处于核心位置。嘌呤合成包括从头合成(de novo purine synthesis)和补救途径(salvage pathway)两个合成途径。
腺苷酸琥珀酸裂解酶缺陷症(adenylosuccinate lyase deficiency ADSL缺陷症)是一种在腺嘌呤从头合成以及嘌呤核苷酸代谢途径中产生缺失、混乱的代谢疾病。该疾病产生的原因主要是由于患者体内的腺苷酸琥珀酸裂解酶发生了突变或者缺失，从而导致细胞中该酶的底物SAICAR过度地积累而得不到及时的清除[Jaeken J，Van den Berghe G.(1984).An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids.Lancet 8411：1058-1061.]。1984年Jaeken以及Van den Berghe首次在几个患有运动迟缓症和自闭症的患者体液中检测到该代谢物的积累。患有腺苷酸琥珀酸裂解酶缺陷症的患者通常会出现严重的发育不良、运动迟缓、目光呆滞、癫痫、自闭等症状[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinate lyase deficiency.Mol Genet Metab 89，19-31.Clamadieu，C.，Cottin，X.，Rousselle，C.，and Claris，O.(2008).Adenylosuccinate lyase deficiency：an unusual cause of neonatal seizure.Arch Pediatr 15，135-138.Castro，M.，Perez-Cerda，C.，Merinero，B.，Garcia，M.J.，Bernar，J.，Gil Nagel，A.，Torres，J.，Bermudez，M.，Garavito，P.，Marie，S.，et al.(2002).Screening for adenylosuccinate lyase deficiency：clinical，biochemical and molecular findings in four patients.Neuropediatrics 33，186-189.Jurecka，A.，Zikanova，M.，Tylki-Szymanska，A.，Krijt，J.，Bogdanska，A.，Gradowska，W.，Mullerova，K.，Sykut-Cegielska，J.，Kmoch，S.，and Pronicka，E.(2008b).Clinical，biochemical and molecular findings in seven Polish patients with adenylosuccinate lyase deficiency.Mol Genet Metab 94，435-442.]。
ADSL缺陷症有3种连续的主要表型：新生儿致死型、重度(I型)和轻到中度(II型)。临床上发现即便是来自同一家族的患者也具有不同的表型。发病一般见于出生至婴幼儿期。已报导的病例有致死的新生脑病变(表现有运动功能减退、难治性癫痫、呼吸障碍)，中度智 力缺陷。所有的患者均存在智力缺陷，大多数存在不同类型的癫痫，约1/3的存在自闭症特征(无法进行眼神交流、对声光敏感、重复性行为、躁动、乱发脾气、自伤和自残)。其他不常见的临床表现包括心理运动延迟、过度活跃、语言障碍、肌肉张力减退、肌肉萎缩和痉挛。重度患者通常小头畸形。产前临床表现报导的有：宫内生长受损、小头畸形、胎儿运动功能减退以及胎儿心率变化缺失。
在腺嘌呤从头合成的代谢途径中，腺苷酸琥珀酸裂解酶(以下简称ADSL酶)主要参与将SAICAR裂解催化形成AICAR以及S-AMP生成AMP的反应[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinate lyase deficiency.Mol Genet Metab 89，19-31.Clamadieu，C.，Cottin，X.，Rousselle，C.，and Claris，O.(2008).Adenylosuccinate lyase deficiency：an unusual cause of neonatal seizure.Arch Pediatr 15，135-138.Castro，M.，Perez-Cerda，C.，Merinero，B.，Garcia，M.J.，Bernar，J.，Gil Nagel，A.，Torres，J.，Bermudez，M.，Garavito，P.，Marie，S.，et al.(2002).Screening for adenylosuccinate lyase deficiency：clinical，biochemical and molecular findings in four patients.Neuropediatrics 33，186-189.]。腺苷酸琥珀酸裂解酶缺陷患者由于ADSL酶发生了突变或者缺失，导致有害代谢物SAICAR得不到及时的清除，通常会出现很严重的神经以及生理的症状，比如癫痫，大脑发育失常，运动呆滞等[Ciardo，F.，Salerno，C.，and Curatolo，P.(2001).Neurologic aspects of adenylosuccinate lyase deficiency.J Child Neurol 16，301-308.Gitiaux，C.，Ceballos-Picot，I.，Marie，S.，Valayannopoulos，V.，Rio，M.，Verrieres，S.，Benoist，J.F.，Vincent，M.F.，Desguerre，I.，and Bahi-Buisson，N.(2009).Misleading behavioural phenotype with adenylosuccinate lyase deficiency.Eur J Hum Genet 17，133-136.Mierzewska，H.，Schmidt-Sidor，B.，Jurkiewicz，E.，Bogdanska，A.，Kusmierska，K.，and Stepien，T.(2009).Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinate lyase deficiency--MRI，clinical，biochemical and neuropathological findings of Polish patients.Folia Neuropathol 47，314-320.]。在患者的脑脊液、体液中，通常会大量积累中间代谢物SAICAr及S-Ado(SAICAr是SAICAR脱去磷酸的产物，S-Ado是S-AMP去磷酸的产物)[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinate lyase deficiency.Mol Genet Metab 89，19-31.Mierzewska，H.，Schmidt-Sidor，B.，Jurkiewicz，E.，Bogdanska，A.，Kusmierska，K.，and Stepien，T.(2009).Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinate lyase deficiency--MRI，clinical，biochemical and neuropathological findings of Polish patients.Folia Neuropathol 47，314-320.]。Van den Berghe等人发现体液中S-do与SAICAr的比值与患者的病症严重性有一定的相关性[Van den Bergh F，Vincent MF，Jaeken J，Van den Berghe G.(1993).Residual adenylosuccinase activities in fibroblasts of adenylosuccinase-deficient  children：parallel deficiency with adenylosuccinate and succinyl-AICAR in profoundly retarded patients and non-parallel deficiency in a mildly retarded girl，J.Inherit.Metab.Dis.16(2)415-424.]。目前，临床上并没有有效的，可以治愈ADSL缺陷症治疗方案。
氨基咪唑琥珀基氨甲酰核苷酸合成酶/氨基咪唑核苷酸羧化酶，即PAICS(phosphoribosylaminoimidazole succinocarboxamidesynthetase/phosphoribosylaminoimidazolecarboxylase)是一种嘌呤从头合成途径中重要的双功能酶，它具有SAICAR合成酶(4-(N-succinylcarboxamide)-5-aminoimidazole ribonucleotidesynthetase，SAICARs)和AIR羧化酶(5-aminoimidazole ribonucleotidecarboxylase，AIRc)的功能，催化嘌呤从头合成代谢第六步、第七步反应，其中的一个关键反应过程如下所示
Figure PCTCN2017101062-appb-000001
发明人在先的研究表明，通过干扰PAICS蛋白(基因)的功能，可以有效减少SAICAR及SAICAr的积累，达到治疗或改善ADSL缺陷症的目的，但是现阶段并未报导有相应的化合物具有这一作用。
发明内容
本发明的目的在于提供影响SAICAR合成的化合物及应用。
发明人基于现有的蛋白结构数据、小分子结构数据，使用软件计算分析，发现DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716的化合物，可以有效干扰PAICS的活性，进而减少SAICAR的合成，最终减少SAICAr的积累，达到治疗或改善ADSL缺陷症的目的。
上述化合物药学上可接受的衍生物，具有与化合物本身相同的母核结构，在体内经过水解等作用，可以生成与原化合物具有相同或相近活性的分子，达到相同或相近的治疗效果。
化合物药学上可接受的衍生物，尤其指其简单衍生物，特别是其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种，即碳原子数在1～6，优选为2～6，2～4的羧酸、醇、胺与母化合物缩合得到的衍生物。
化合物药学上可接受的药用盐可以通过常规的化学方法从母体化合物合成，如在Pharmaceutical Salts：Properties，Selection，and Use，P.Heinrich Stahl(Editor)，Camille G.Wermuth(Editor)，ISBN：3-90639-026-8，Hardcover，388pages，August 2002中描述的方法。一般来说，这些盐可以由化合物的游离碱和酸在水或有机溶剂或二者的混合液中反应制得；通常， 使用非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈。
酸加成盐可以通过各种酸(无机酸和有机酸)制得。酸加成盐的实例包括由酸制成的盐，所述酸选自由乙酸、2，2-二氯乙酸、己二酸、藻酸、抗坏血酸(如L-抗坏血酸)、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、丁酸、(+)樟脑酸、樟脑-磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环拉酸、十二烷基硫酸、乙烷-1，2-二磺酸、乙烷磺酸、2-羟乙基磺酸、甲酸、富马酸、半乳糖酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、葡萄糖醛酸(如D-葡萄糖醛酸)、谷氨酸(如L-谷氨酸)、α-酮戊二酸、乙醇酸、马尿酸、氢溴酸、盐酸、氢碘酸、羟乙磺酸、(+)-L-乳酸、(±)-DL-乳酸、乳糖酸、马来酸、苹果酸、(-)-L-苹果酸、丙二酸、(±)-DL-扁桃酸、甲基磺酸、萘-2-磺酸、萘-1，5-二磺酸、1-羟基-2-萘酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、帕莫酸、磷酸、丙酸、L-焦谷氨酸、水杨酸、4-氨基-水杨酸、癸二酸、硬脂酸、丁二酸、硫酸、单宁酸、(+)-L-酒石酸、硫氰酸、p-甲苯磺酸、十一碳烯酸和戊酸，以及酰化氨基酸和阳离子交换树脂组成的组。
通过联合使用上述化合物中的至少两种，有望获得更佳的治疗或改善ADSL缺陷症的效果。
附图说明
图1是PAICS的三维彩带(solid ribbon)结构图；
图2是CAIR和SAICAR合成酶在晶体结构中的相互作用图，图中A：PDB access ID 2GQS；B：PDB access ID 2CNQ；C：PDB access ID 4FE2；
图3是不同种SAICAR合成酶蛋白序列对齐结果。
具体实施方式
人PAICS蛋白质序列全长425个氨基酸残基，其中2～260AA为SAICAR synthetase结构域，267-425为AIR carboxylase结构域，两结构域由6肽(KSESQC)连接。此外，SAICAR Synthetase结构域的GLN159～GLN183α螺旋和AIR carboxylase结构域的ASN395～ASN424α螺旋相互作用，紧密结合这一起，如图1所示。
在蛋白质结构数据库中(RCSB)，收录了不同来源的SAICAR synthetase晶体结构数据，其中包括Saccharomyces cerevisiae(1A48，2CNQ，2CNV，2CNU，1OBD，1OBG)、Pyrococcus horikoshii OT3(3U54，3U55)、Escherichia coli(2GQR，2GQS)、Methanocaldococcus jannaschii(2YZL，2Z02)、Streptococcus pneumonia(4FGR，4FE2)、Mycobacterium abscessus ATCC 19977/DSM 44196(3R9R)、Thermotoga maritime(1KUT)、Clostridium perfringens(3NUA)、Ehrlichia chaffeensis(3KRE)、Geobacillus kaustophilus(2YWV)。以及PAICS晶体结构数据Homo sapiens(2H31)和Bombyx mori(4JA0)。其中复合物中含有CAIR的结构有2GQS、2CNQ 和4FE2，含有ASP的结构有2CNV、2CNU和4FE2。
如图2，在2CNQ中CAIR 
Figure PCTCN2017101062-appb-000002
以内的残基Arg122、Ser128、ASP215、Arg242和Arg264；2GQS中CAIR 
Figure PCTCN2017101062-appb-000003
以内的残基Arg94、Ser100、ASP129、ASP175、Arg199和Arg215；4FE2中CAIR 3埃以内的残基Arg93、Ser99、ASP174、Arg199、Arg214。对照不同物种来源的SAICAR蛋白序列对齐结果(图3)，可以看出不同物种SAICAR synthetase与CAIR的结合呈现高度保守性，主要以氢键作用固定CAIR。
基于以上结果，同时考虑到人的PAICS晶体结构中没有结合CAIR的构象，催化区域没有形成催化构象。进行计算筛选得到的结果不可靠。因此采用Saccharomyces cerevisiae(PDB：2CNQ)和Escherichia coli(PDB：2GQS)SAICAR合成酶晶体结构中的构象作为计算筛选的受体结构。采用Discovery studio的ligand fit模块，对DrugBank(http://www.drugbank.ca/downloads#structures)中的4661种小分子药物进行计算筛选。按对接得分排序，选取前500个构象，剔除重复后，得到的重点筛选结果如表1所示。
表1、计算筛选结果
Figure PCTCN2017101062-appb-000004
计算机筛选结果表明表中的化合物均可以有效与PAICS作用，影响SAICAR的合成，有望开发为ADSL缺陷症的治疗药物或保健品。
生化酶活实验、细胞生物学实验确证，化合物对SAICAR的蓄积抑制率如下：
DrugBank ID 对SAICAR的蓄积抑制率
DB01661 86.6％
DB01868 82.5％
DB02578 62.9％
DB02696 58.6％
DB02716 77.7％
通过对PAICS活性的抑制，导致有毒化合物SAICAR的蓄积下降，从而证明可以有效治疗罕见病ADSL缺陷症。
上述化合物药学上可接受的衍生物，具有与化合物本身相同的母核结构，在体内经过水解等作用，可以生成与原化合物具有相同或相近活性的分子，达到相同或相近的治疗效果。
化合物药学上可接受的衍生物，尤其指其简单衍生物，特别是其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种，即碳原子数在1～6，优选为2～6，2～4的羧酸、醇、胺与母化合物缩合得到的衍生物。
化合物药学上可接受的药用盐可以通过常规的化学方法从母体化合物合成，如在Pharmaceutical Salts：Properties，Selection，and Use，P.Heinrich Stahl(Editor)，Camille G.Wermuth(Editor)，ISBN：3-90639-026-8，Hardcover，388pages，August 2002中描述的方法。一般来说，这些盐可以由化合物的游离碱和酸在水或有机溶剂或二者的混合液中反应制得；通常，使用非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈。
酸加成盐可以通过各种酸(无机酸和有机酸)制得。酸加成盐的实例包括由酸制成的盐，所述酸选自由乙酸、2，2-二氯乙酸、己二酸、藻酸、抗坏血酸(如L-抗坏血酸)、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、丁酸、(+)樟脑酸、樟脑-磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环拉酸、十二烷基硫酸、乙烷-1，2-二磺酸、乙烷磺酸、2-羟乙基磺酸、甲酸、富马酸、半乳糖酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、葡萄糖醛酸(如D-葡萄糖醛酸)、谷氨酸(如L-谷氨酸)、α-酮戊二酸、乙醇酸、马尿酸、氢溴酸、盐酸、氢碘酸、羟乙磺酸、(+)-L-乳酸、(±)-DL-乳酸、乳糖酸、马来酸、苹果酸、(-)-L-苹果酸、丙二酸、(±)-DL-扁桃酸、甲基磺酸、萘-2-磺酸、萘-1，5-二磺酸、1-羟基-2-萘酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、帕莫酸、磷酸、丙酸、L-焦谷氨酸、水杨酸、4-氨基-水杨酸、癸二酸、硬脂酸、丁二酸、硫酸、单宁酸、(+)-L-酒石酸、硫氰酸、p-甲苯磺酸、十一碳烯酸和戊酸，以及酰化氨基酸和阳离子交换树脂组成的组。
组合用药在一定程度上可以提高疗效，减少毒副作用。优选的，可以同时使用2种、3种、4种、5种或更多种化合物或其衍生物作为治疗ADSL缺陷症的活性成分。

Claims (15)

  1. 化合物或其药学上可接受的衍生物在制备SAICAR合成酶活性干扰剂或抑制剂中的应用，其中，化合物的DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716。
  2. 根据权利要求1所述的应用，其特征在于：SAICAR合成酶为PAICS。
  3. 根据权利要求1所述的应用，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  4. 根据权利要求3所述的应用，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  5. 化合物或其药学上可接受的衍生物在制备ADSL缺陷症治疗或缓解药物或保健品中的应用，其中，化合物的DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716。
  6. 根据权利要求5所述的应用，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  7. 根据权利要求6所述的应用，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  8. 一种治疗或缓解ADSL缺陷症的组合物，其特征在于：其活性成分选自DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716的化合物中，或其药学上可接受的衍生物中的至少两种。
  9. 根据权利要求8所述的组合物，其特征在于：其活性成分选自DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716的化合物中，或其药学上可接受的衍生物中的至少3种。
  10. 根据权利要求8或9所述的组合物，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  11. 根据权利要求10所述的组合物，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  12. 根据权利要求8所述的组合物，其特征在于：组合物还包括药学或食品上可接受的辅料。
  13. 治疗或缓解ADSL缺陷症的方法，包括给予患者治疗量的化合物或其药学上可接受的衍生物，其中，化合物的DrugBank ID为DB01661、DB01868、DB02578、DB02696、DB02716。
  14. 根据权利要求13所述的方法，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  15. 根据权利要求13所述的方法，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
PCT/CN2017/101062 2016-09-29 2017-09-08 影响saicar合成的化合物及应用 WO2018059214A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610865163.5 2016-09-29
CN201610865163 2016-09-29

Publications (1)

Publication Number Publication Date
WO2018059214A1 true WO2018059214A1 (zh) 2018-04-05

Family

ID=61762495

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/CN2017/101066 WO2018059216A1 (zh) 2016-09-29 2017-09-08 降低saicar合成酶活性的化合物及应用
PCT/CN2017/101062 WO2018059214A1 (zh) 2016-09-29 2017-09-08 影响saicar合成的化合物及应用
PCT/CN2017/101064 WO2018059215A1 (zh) 2016-09-29 2017-09-08 降低saicar累积的化合物及应用
PCT/CN2017/103405 WO2018059395A1 (zh) 2016-09-29 2017-09-26 减弱saicar合成酶活性的化合物及应用
PCT/CN2017/103408 WO2018059396A1 (zh) 2016-09-29 2017-09-26 一类减少saicar累积的化合物及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/101066 WO2018059216A1 (zh) 2016-09-29 2017-09-08 降低saicar合成酶活性的化合物及应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/CN2017/101064 WO2018059215A1 (zh) 2016-09-29 2017-09-08 降低saicar累积的化合物及应用
PCT/CN2017/103405 WO2018059395A1 (zh) 2016-09-29 2017-09-26 减弱saicar合成酶活性的化合物及应用
PCT/CN2017/103408 WO2018059396A1 (zh) 2016-09-29 2017-09-26 一类减少saicar累积的化合物及应用

Country Status (4)

Country Link
US (1) US11766412B2 (zh)
EP (1) EP3524614A4 (zh)
JP (1) JP6892916B2 (zh)
WO (5) WO2018059216A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059216A1 (zh) 2016-09-29 2018-04-05 广州君赫生物科技有限公司 降低saicar合成酶活性的化合物及应用
CN110678452B (zh) 2017-04-20 2023-02-28 广州君赫生物科技有限公司 亚精胺及其衍生物的应用
CA3057206C (en) 2017-04-20 2022-11-01 Geneheal Biotechnology Co., Ltd. Applications of spermine and its derivative in preparation of antitumor drug
WO2018192318A1 (zh) * 2017-04-20 2018-10-25 广州君赫生物科技有限公司 干扰saicar合成酶活性化合物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001036A1 (en) * 1988-07-20 1990-02-08 Medivir Ab Nucleoside derivatives
WO2003062255A2 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH430712A (fr) * 1965-06-09 1967-02-28 Kogerim Ets Procédé de préparation de formes stables et biologiquement actives des co-enzymes pyridoxiniques
JPS5998015A (ja) * 1982-11-27 1984-06-06 Microbial Chem Res Found 免疫賦活剤
CA1305425C (en) * 1986-12-02 1992-07-21 Raymond J. Bergeron Anti-neoplastic spermine derivative
US4952585A (en) 1988-12-15 1990-08-28 Merrell Dow Pharmaceuticals Inc. Castanospermine esters in the inhibition of tumor metastasis
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
WO1997011691A1 (en) 1995-09-29 1997-04-03 Children's Medical Center Corporation Treatment of human prostate cancer with spermine
US6235794B1 (en) * 1997-04-03 2001-05-22 University Of Florida Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
AU3133399A (en) 1998-04-03 1999-10-25 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US20030022209A1 (en) * 2001-06-05 2003-01-30 Lori Friedman ADSLs as modifiers of the p53 pathway and methods of use
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
EP1492564A2 (en) * 2001-10-31 2005-01-05 Université Libre de Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
US6660719B2 (en) * 2001-12-17 2003-12-09 Biocryst Pharmaceuticals Inc. Inhibiting T-Cell proliferation
JP2005521929A (ja) * 2002-03-29 2005-07-21 ジェノマティカ・インコーポレイテッド ヒト代謝モデルおよび方法
US8949032B2 (en) * 2002-03-29 2015-02-03 Genomatica, Inc. Multicellular metabolic models and methods
US7056945B1 (en) * 2002-06-14 2006-06-06 The Regents Of The University Of California Selective inhibition of neuronal nitric oxide synthase
ITMI20031570A1 (it) * 2003-07-31 2005-02-01 Giuliani Spa Composizione per uso dietetico, farmaceutico o cosmetico
WO2006099095A2 (en) * 2005-03-11 2006-09-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ribosome inhibitors as inhibitors of tyrosyl-dna-phosphodiesterase
US20080176907A1 (en) * 2006-09-19 2008-07-24 Northwestern University NOS Inhibitors For Treatment Of Motor Deficit Disorders
CN101037423A (zh) 2007-04-16 2007-09-19 河南大学 高亚精胺缀合物、制备及其应用
US20090030005A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
US20140127820A1 (en) * 2011-06-29 2014-05-08 The Oregon State Board Of Higher Education On Behalf Of Portland State University Analyte detection using near-infrared fluorophores
FR2980709B1 (fr) 2011-09-29 2013-10-25 Nutrialys Medical Nutrition Sa Compositions contenant de la spermine et compositions pharmaceutiques les contenant
US20140141010A1 (en) * 2012-06-25 2014-05-22 Connexios Life Sciences Pvt. Ltd. Use of adsl activator to achieve glycemic control in mammals
WO2014067038A1 (zh) * 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 治疗人类adsl缺陷症的靶点、制剂及方法
EP2928458A4 (en) 2012-11-14 2016-09-07 Biomark Technologies Inc SPERMIDINE / SPERMIN N'-ACETYLTRANSFERASE SUBSTRATES AS ANTICANCER DRUG COMPOUNDS
EP2950820A4 (en) 2013-01-30 2016-08-03 Biomark Technologies Inc SPERMIDINE / SPERMIN N1-ACETYLTRANSFERASE ANTIBODY AS ACTIVE AGGREGATES AGAINST CANCER
US20160369281A1 (en) * 2015-06-16 2016-12-22 Geneheal Biotechnology Co., Ltd. Target point, preparation and method for treating human ADSL deficiency
FR3054963B1 (fr) * 2016-08-10 2018-09-14 Assistance Publique-Hopitaux De Paris (Ap-Hp) Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase
CN106399380A (zh) 2016-09-13 2017-02-15 上海云舜生物技术有限公司 含抗pd‑1基因和聚亚精胺的复合物及其在治疗肿瘤中的应用
WO2018059216A1 (zh) * 2016-09-29 2018-04-05 广州君赫生物科技有限公司 降低saicar合成酶活性的化合物及应用
WO2018059211A1 (zh) 2016-09-29 2018-04-05 广州君赫生物科技有限公司 精胺及其衍生物的新应用
CN110678452B (zh) 2017-04-20 2023-02-28 广州君赫生物科技有限公司 亚精胺及其衍生物的应用
CA3057206C (en) 2017-04-20 2022-11-01 Geneheal Biotechnology Co., Ltd. Applications of spermine and its derivative in preparation of antitumor drug

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001036A1 (en) * 1988-07-20 1990-02-08 Medivir Ab Nucleoside derivatives
WO2003062255A2 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. Sugar modified nucleosides as viral replication inhibitors
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIPPERFIEL, J.R. ET AL.: "Effects on the Activity of the Enzyme Phosphoribosyl-Aminoimidazole Carboxylase, 5'-Phosphate", NUCLEOSIDES AND NUCLEOTIDES, vol. 7, no. 5-6, 31 December 1988 (1988-12-31), pages 571 - 576 *
MACKENZIE, G. ET AL.: "Synthesis of Analogues of 5 -Aminoimidazole Ribonucleotides and their Effects as Inhibitors and Substrates of the Enzymes, Phosphoribosylaminoimidazole Carboxylase and PhosphoribosylaminoimidazolesuccinocarboxamideSynthetase Involved in the Biosynthesis of Purine Nucleotides de novo", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, vol. 12, 1 January 1976 (1976-01-01), pages 453 - 455, XP055500446 *

Also Published As

Publication number Publication date
US11766412B2 (en) 2023-09-26
JP6892916B2 (ja) 2021-06-23
EP3524614A1 (en) 2019-08-14
WO2018059396A1 (zh) 2018-04-05
WO2018059215A1 (zh) 2018-04-05
WO2018059395A1 (zh) 2018-04-05
JP2020503242A (ja) 2020-01-30
EP3524614A4 (en) 2020-06-10
US20190209499A1 (en) 2019-07-11
WO2018059216A1 (zh) 2018-04-05

Similar Documents

Publication Publication Date Title
US20230348981A1 (en) Methods and compositions for inhibiting and treating neurological conditions
WO2018059214A1 (zh) 影响saicar合成的化合物及应用
WO2018059212A1 (zh) 减少saicar累积的化合物及应用
WO2018192323A1 (zh) 亚精胺及其衍生物的应用
EP3613416B1 (en) Applications of spermine and its derivative in preparation of antitumor drug
WO2020081923A1 (en) Inhibitors of sarm1 in combination with nad+ or a nad+ precursor
WO2019113724A1 (zh) 双硫仑的新应用
WO2019033257A1 (zh) 化合物干扰saicar合成酶活性的新应用
WO2018192318A1 (zh) 干扰saicar合成酶活性化合物的应用
WO2022095809A1 (zh) 影响saicar表达量的化合物的新应用
WO2020140730A1 (zh) 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用
WO2020147471A1 (zh) 天冬氨酸的新应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17854664

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17854664

Country of ref document: EP

Kind code of ref document: A1